130 redundancies at Janssen Pharmaceutica (Beerse)

Janssen is part of the American Johnson & Johnson. The company previously said the company must “adapt to continue to meet patient needs in the future.” “We develop activities in a complex and rapidly changing environment,” it said.

The unions are already satisfied that they have reduced the figure slightly. “In the coming days we will see if we can offer more resistance, but that will be difficult,” says Serge Seret of the socialist union. “We will in any case ensure that as many people as possible leave voluntarily.” Three works councils will follow in the coming weeks, the last being on October 23.

Despite the satisfaction, the unions continue to insist that they do not consider Janssen’s way of thinking correct. “It’s about securing future profits,” Seret said. “It’s the dynamics of the company, it’s just their way of working.”

A total of 5,309 people work for Janssen in our country. Expiry of a patent in 2025 (Stelara, ed.) would have prompted the pharmaceutical company to implement the reorganization. Stelara is one of Janssen’s most profitable medicines. Losing that exclusivity therefore has a significant impact.